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A B S T R A C T
Orexin neurons are discretely localized within the lateral hypothalamus and have widespread projections into all
areas of the brain. In addition, several lines of evidence specify that orexins may also participate in the reg-
ulation of a variety of affective and cognitive processes. The Orexin-1 receptor (OX1r) is distributed extensively
throughout the prefrontal cortex (PFC). Delay-based decision- making is mediated largely by the orbitofrontal
cortex (OFC) while effort- based decision-making is controlled by the anterior cingulated cortex (ACC). Hence, in
the present study, a series of experiments were conducted to clarify the role of OX1r in the mPFC (ACC and/or
OFC) in cost and benefit decision-making. The rats were trained in a delay and/or effort-based form of cost-
benefit T-maze decision-making task. Two goal arms were different in the amount of accessible reward and cost.
Before surgery, all animals were selecting the high reward arm and pay the cost on almost every trial. During the
test days, the rats received local injections of either DMSO 20% /0.5 μl, as a vehicle, or SB334867 (3, 30 and
300 nM/0.5 μl), as a selective OX1r antagonist, within the ACC and/or OFC. The results of this study showed that
the bilateral microinjection of SB334867 into ACC and/or OFC changed the preference to a low reward arm with
no cost, indicating the role of OX1 receptors in cost and benefit decision- making. From these results, it can be
implied that OX1 receptors in the mPFC play a crucial role for allowing the animal to evaluate and pay the cost
to acquire greater rewards.
1. Introduction
The orexins are neuropeptide transmitters made exclusively in hy-
pothalamic neurons that have extensive central nervous system (CNS)
projections. The orexins constitute two peptides (orexin A and orexin B)
which have two receptors (OX1r and OX2r). While the Orx2r has an
equal affinity for both ligands, the Orx1r binds OrxA with a tenfold
greater affinity relative to OrxB (Sakurai et al., 1998). Orexin is mainly
expressed by neurons located in the posterior of the hypothalamus.
Despite being small in number, these neurons release orexin through
the CNS and affect a variety of physiological functions including sleep,
hunger, and drug abuse (Sakurai et al., 1998; Mahler et al., 2012;
Ritchie et al., 2010; Thannickal et al., 2000). Orexin neurons can be
putatively organized into three cell-clusters in the hypothalamus: a
cluster in the dorsomedial hypothalamus, perifornical area (PeF), and
the lateral hypothalamus (LH). PeF predominantly contains neurons
that are activated during cortical activations (Kostin et al., 2012). There
are several reasons to believe that orexin might also be important in
motivating cost-benefit decisions. The orexin system has also been
implicated in reward behaviors (Aston-Jones et al., 2010), in arousal
(Sutcliffe and de Lecea, 2002; Sakurai, 2007). Additionally, orexin is
thought to play an important role in different forms of learning and
memory (Akbari et al., 2006; Akbari et al., 2007; Aou et al., 2003;
Jaeger et al., 2002).
“Decision-making is an adaptive behavior that takes into account
several internal and external input variables and leads to the choice of a
course of action over other available and often competing alternatives”
(Khani et al., 2015). The costs and benefits must be weighed before
deciding on which course of action to choose and recent studies have
shown the relationship between some brain regions and calculating the
cost of actions. The anterior cingulate cortex (ACC) is located in a un-
ique position in the brain and is connected to both the limbic system as
well as the “emotional” and the prefrontal cortex “cognition” (Euston
et al., 2012). ACC plays a crucial role in initiation, motivation, and
goal-directed behaviors (Devinsky et al., 1995). A number of studies
indicate that the ACC is involved in cost evaluation (Rushworth et al.,
2004). Recent studies have demonstrated that the ACC plays a basic
role in effort-based decision-making (Walton et al., 2003; Schweimer
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and Hauber, 2005). The ACC has a fundamental role in both learning
and using extended action-outcome histories to optimize voluntary
choice behavior (Kennerley et al., 2006).
The orbitofrontal cortex (OFC) is the portion of the prefrontal cortex
that is important for detecting and tracking the value of a stimulus
(Rolls, 2000). The OFC is also activated when an expected reward is not
obtained and when behavior should be changed (Rolls, 2000). The OFC
plays a key role in processing reward. It integrates multiple sources of
information about the reward outcome to originate a value signal. In
effect, OFC calculates how rewarding a reward is (Wallis, 2007). In
2006, Rudebeck et al. reported that OFC is involved in delay-based
decision-making (Rudebeck et al., 2006). A previous study showed that
the systemic administration of SB334867 reduced the subjects' will-
ingness to expend effort for high-fat chocolate food over regular food in
effort-based decision-making task (Borgland et al., 2009). An earlier
study showed that there is a direct projection from LH to mPFC with
rostro-caudally gradient and the expression of OX1r in the ACC (Jin
et al., 2016). The OFC is densely connected to the hypothalamus and
the lateral OFC is an important region for the delay-based decision-
making (Hirose et al., 2016). Since there is limited knowledge about the
role of the hypothalamic-cortical orexinergic system in the decision-
making process, this study aimed to determine the involvement of OX1r
in the ACC and OFC regions in the reduction of the preference for ex-
panding an effort to obtain a high reward in T-maze decision–making
task in rats.
2. Materials and methods
2.1. Animals
42 male Wistar rats (Pasteur Institute, Iran) were used as subjects.
Rats were 8 weeks old at their arrival to the animal facility. Rats were
housed in groups of three per cage under standard conditions in a
temperature-controlled room and maintained on a standard 12/12 h
light/dark cycle (lights on at 07:00 am). Water was available ad li-
bitum. The animals were handled on a daily basis and food was ad-
justed for initial body weights of about 85% of the free feeding weight
during the beginning of the behavioral experiment (190–220 g) and
after this a controlled weight gain of about 6–12 g per week. All animals
were naïve to the current tests and had no experience in any behavioral
experiments.
2.2. Drugs
In this study, the drugs used were as follows: SB334867 (Tocris
Bioscience, Bristol, UK), as an OX1r antagonist, was dissolved in 20%
dimethyl sulfoxide (DMSO; Sigma Aldrich, Germany). Control animals
received DMSO 20% as a vehicle.
2.3. Apparatus
T-mazes were used adopted with parameters from the study by Denk
in 2005 (Denk et al., 2005). The Plexiglas mazes had three arms each
60 cm long, 10 cm wide and 40 cm high. Four retractable doors were
built in the goal arms of the maze. One door was placed just before the
food at each arm, 5 cm from the end of the arm and the other after the
entrance into each arm, 12.5 cm from the entrance point. The doors
were used in delay-based decision-making task to delay the access of
the animals to rewards (Fig. 1). Furthermore, there were grooves at the
beginning of the entrance to each goal arm in both mazes, where a
barrier of 10 cm width and 40 cm height could be placed on certain
trials to force the animal to go to one of the goal arms (“forced” trials).
2.4. Behavioral training
Before the start of training, the rats were handled every day for one
week to familiarize them with human contact and were put on a re-
stricted feeding schedule. When they reached 85% of their free-feeding
weight, the rats were introduced to the T-maze.
2.4.1. Habituation phase
On the two days, the animals were placed in the start arm in cages of
three and were allowed to explore the maze for 10min. Plentiful food
was left in both feeding wells in the goal arms. The third and fourth
days of habituation were identical except for the fact that each animal
investigated the maze individually. At the end of these 2 days, all of the
rats were eating the pellets in the food wells (45mg food-reinforcement
pellets, Formula A/I; P. J. Noyes, Lancaster, NH).
2.4.2. Discrimination phase
The first phase of discrimination training involved putting ten pel-
lets in the feeding well of one goal arm [high food arm (HRA)] and two
pellets in the other goal arm [low food arm (LRA)]. For half of the rats,
the HRA was to the left, and, for the others, it was to the right. The side
of the maze that served as the HRA was the same for each subject
throughout all experiments. Initially, each rat was placed in the start
arm and was allowed to choose both food arms on each trial. Five trials
ran each day over 2 d. For the next 2 d, the rats were moved onto the
second phase in which access to one of the goal arms was prevented by
placing a door at its entrance (forced trials), thus forcing the rat to
sample a particular arm on each trial. The order of the forced trials was
determined pseudo randomly so that they never had more than two
consecutive turns to either side. There were 10 trials run per day for
each animal. On each day, at first each rat received two forced trials,
one to each goal arm, then 8 choice trials, with an inter-trial interval of
approximately 5min. The rats were removed from the maze after eating
the food in the selected arm without being able to sample from the
other arm. This protocol was used throughout all experiments.
2.4.3. Effort-based decision-making task
After rats had learned the unequal size of the reward, they then
underwent barrier training. When 80% of choices were HRA with the
10-cm barrier for each rat the barrier height was increased to 20 cm.
Rats were given three training days with a 20-cm barrier and 3 days
with a 30-cm barrier. In experiment 1a (n=16) the barrier introduced
just for high reward arm (differential effort) but for experiment 1b
(n=6) the barriers introduced for both arms (equal effort).
2.4.4. Delay-based decision-making task
After the rats had learned the different size of reward, a delay of 5 s
was introduced into the HRA, meaning that in the LRA the rat received
it immediately two food pellets, whereas in the HRA it had to wait5 s,
confined in the arm by the movable gates, before receiving ten food
pellets. Each day rats received ten trials, two forced and eight choice
trials. Once rats chose the HRA on at least 80% of trials in 3 days, the
delay was increased to 10 s, and then to 15 s after the same criteria was
met. In experiment 2a (n=14) the delay introduced for high reward
arm (differential delay) and in experiment 2b (n=6) delay introduced
for both arm (equal delay).
2.5. Surgery
Anesthesia was achieved using a mixture of Ketamine (100mg/kg)
and Xylazine (8mg/kg) intraperitoneal (i.p.) injection, and then rats
were immobilized in a stereotaxic device (Stoelting Co., USA). An in-
cision was made along the midline on the head of the rats and the skull
was exposed. 23 gauge stainless steel guide cannulae were implanted
bilaterally 1mm above the target locations. The coordinates for target
locations were determined from a rat brain atlas (Paxinos and Watson,
2007) as follows: 3.7mm anterior to bregma, 2.2mm lateral to the
midline, and 5mm ventral to the skull for OFC and 1.2mm anterior to
bregma, 0.7mm lateral to midline and 3mm ventral to the skull is the
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coordination of the ACC. After securing the guide cannulae in place,
dental acrylic cement (Paladur) was applied to fix the implants. Fol-
lowing the surgery, rats were housed individually, were monitored on a
daily basis, and were allowed to recover from the surgery at least for
10 days before restarting any behavioral training. For 2 days before the
surgery and during the recovery period, rats had free access to food and
water.
2.6. Experimental design
Following recovery from the surgery and reestablishment of the
restricted food regime, the animals completed two “forced decision”
trials before eight “choice” trials of T-maze decision-making task per
day, until they reached the pre-surgery performance rate. To ensure
steady behavior, the training was continued for 5 days. During the test
days, after the “forced decision” trials, the animals received bilateral
microinjection of either SB334867 (OX1r antagonist) or DMSO 20%
(0.5 μl/per side) in the OFC or ACC in a counterbalanced manner; the
animals that received local SB334867treatment on the first test day
were subjected to local vehicle treatment and vice versa. The animals
performed the task for 3 days without any manipulation between test
days and microinjection day.
All microinjections were administered in a volume of 0.5 μl per side
over 60 s using a stainless steel needle (30gauge) which was directly
inserted into the guide cannula, protruding 1mm beyond the tip of the
cannula. Polyethylene tubing (PE-20) connected the injector cannula to
a 1-μl Hamilton syringe. The injectors were left in place for 60 s after
the injection to allow diffusion and were then replaced by the stylets.
After the microinjections, the behavioral testing was continued in ex-
actly the same way as before and the animals' behavior was recorded.
In experiment 1 after the completion of all behavioral testing with
microinjection in the effort-based decision task, the animals were
trained on a control task in which a similar 30 cm height barrier was
newly introduced also to the LRA (equal effort), to test possible in-
volvement of locomotor activity, spatial preference or memory in the
decisions of the animals. The training continued for about 10 days to
ensure that the changed rule was well established for the animals. On
the test days, the animals received microinjections of SB334867 or
DMSO 20% (0.5 μl/per side) in the ACC in a counterbalanced manner
and behavioral parameters were analyzed as above.
For experiment 2 after the completion of all behavioral testing with
microinjection in the delay-based decision task, the animals were
trained on a control task in which a similar 15 s delay was newly in-
troduced also to the LRA (equal delay), to test possible involvement of
locomotor activity, spatial preference or memory in the decisions of the
animals. The training continued for about 10 days to ensure that the
changed rule was well established for the animals. On the test days, the
animals received microinjections of SB334867 or DMSO 20% (0.5 μl/
per side) in the OFC as a counterbalance manner and behavioral
parameters were analyzed as above.
2.7. Transient time
For all trials in both experiments, a transient time was calculated.
Transient time was defined as a time from a start point to decision point
before chose an arm (Fig. 1).
2.8. Decision time
In both experiments and for all trials a time spending during making
a decision (Decision time) was calculated. Decision time was defined as
a time from a decision.
2.9. Locomotor activity
In all cost-benefit decision-making tasks, the effect of factors such as
memory, locomotor ability, or possible spatial preferences in the make
a decision is controlled by the equal cost control experiments. However,
in this investigation, we added another control experiment for sur-
veying the role of locomotor activity in the decision making. Changes in
the activity level as a result of orexinergic system deactivation may bias
animals' choice in the presence of differential costs. Two separate
groups of rats were implanted with cannulae aimed at the ACC or OFC.
The coordinates and surgery procedure were the same as described
above. Both groups received SB334867 in the ACC/OFC. Five minutes
after microinjection, rats were placed in the center of an open field
measuring 30 cm×30 cm with 30 cm walls and were allowed to freely
move inside the arena for 10min. The activity was recorded through a
3CCD camera (Panasonic Inc., Japan) mounted 2m above the open
field and was analyzed offline using Ethovision video tracking software
(version 3.1, Noldus Information Technology, The Netherlands).The
distance traveled for 10min were analyzed.
2.10. Histology
After completion of behavioral testing, the animals were deeply
anesthetized with Ketamine and Xylazine. Then, they were transcar-
dially perfused with 0.9% saline and 10% formalin solution. The brains
were removed, blocked and cut coronally in 50m sections through the
cannulae placements. The neuroanatomical location of cannulae tips
placements were confirmed using a rat brain atlas. Only the animals
with correct cannulae placements were included in the data analysis.
Schematic illustrations of coronal sections of the rat brain showing the
approximate location of the OFC and ACC injection sites in the ex-
periments (Fig. 2). The numbers indicate anterioposterior coordinates
relative to bregma. Atlas plates are adapted from Paxinos and Watson
(Paxinos and Watson, 2007).
2.11. Statistics
Data is expressed as mean ± SEM (standard error of the mean). The
data were analyzed by commercially available software GraphPad
Fig. 1. Schematic illustration of the apparatus. T-maze
decision-making task (main task). The apparatus has
three arms including start, high reward and low re-
ward arms.(A) Effort-based T-maze decision-making
task. The animals could choose between a low reward
and a high-reward arm. They could climb over a wire
mesh barrier (30 cm) to obtain ten pellets in the HRA.
(B) Delay-based the animals could choose to wait (15 s)
in order to obtain a higher reward (10 pellets) and/or
choose to receive low reward (2 pellets) immediately.
(C) Transient time was calculated from entrance point
to end of entrance arm and decision time from end of
entrance point to A point. HRA, High reward arm; LRA,
Low reward arm.
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Prism® 5.0. In order to compare the percentage of high reward choice
(HRC), transient time and decision time in all groups (vehicle and ex-
perimental groups), two-way analysis of variance (ANOVA) followed by
post hoc Bonferroni was used as needed. P-values< .05 (P < .05) were
considered to be statistically significant.
3. Results
3.1. Effect of ACC OX1 receptors blockade on the effort-based decision-
making
3.1.1. Differential effort
After recovery from surgery, the animals were trained until the
percentage of HRC reestablished to its level on the day before surgery
for three consecutive days. On test day, different doses of SB334867 (3,
30 and 300 μM/0.5 μl DMSO) or DMSO 20% (0.5 μl/per side)were ad-
ministrated into the ACC. Two-way repeated measure ANOVA followed
by Bonferroni test [Treatment effect: F(3,23)= 4.54, P= .0122; Day
effect: F(3,69)= 18.75, P < .0001; Treatment × Day: F(9,69)= 2.58,
P= .0126)] revealed that blockade of ACC OX1r significantly de-
creased tending to HRC and in these animals, HRC percent significantly
decreased compared to vehicle-control group (Fig. 3A). The maximum
effect was at the doses of 30 (P < .001). Thus, the activation of OX1r in
the ACC affected the preference of animals from deciding to pass the
barrier for getting a large reward to choose to receive a small reward
without any cost.
3.1.2. Equal effort
In addition, we trained the SB334867 (30 μM)-treated animals on an
additional equal control task to determine possible involvement of
spatial preference or memory in the decisions of the animal. In this task,
there was the equal cost (30 cm barrier) but different reward (10 pellets
vs 2 pellets) in both HRA and LRA. Two-way repeated measure ANOVA
followed by Bonferroni test [Treatment effect: F(1,9)= 2.12, P= .179;
Day effect: F(3,27)= 0.24, P= .37; Treatment × Day: F(3,27)= 1.09,
P= .86)] revealed that in equal control task,SB334867 -treated animals
preferred high/delay reward and there was no significant reduction in
HRC percentage compared to vehicle-control group in this task
(Fig. 3B).
3.2. Effect of ACC OX1 receptors on transient and decision-making time in
the effort-based decision-making
Two-way repeated measure ANOVA followed by Bonferroni test
[Treatment effect: F(3,18)= 0.80, P= .51; Day effect: F(3,54)= 2.88,
P < .04; Treatment × Day: F(9,54)= 0.89, P= .5437)] showed that
administration of different doses of SB334867 into the ACC had no
effect on transient time compared to vehicle-control group (Fig. 4A).
The results showed that ACC administration of SB334867had no effect
on decision time [Treatment effect: F(3,17)= 0.84, P= .4921; Day
effect: F(3,51)= 14.2, P < .0001; Treatment × Day: F(9,51)= 1.27,
P= .2748); Fig. 4B].
Fig. 2. Coronal schematic sections show the injection sites in A) the ACC and B) OFC.
[○ Vehicle; ● SB334867; ▲ Misplacement]. CPu, Caudate putamen (striatum); cc, Corpus callosum; cg, Cingulum; M2, Secondry motor cortex; S1FL, Primary
somatosensory cortex, forelimb region; S1J, Primary somatosensory cortex, jaw region; AcbC, Accumbens nu, core; cg1, Cingulate cortex area 1; PrL, Prelimbic
cortex; Fmi, Forceps minor of corpus callosum; IL, Infralimbic cortex; VO, Ventral orbital cortex; MO, Medial orbital cortex. Adopted from “The Rat Brain in
Stereotaxic Coordinates” (Denk et al., 2005).
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3.3. Effect of OFC OX1 receptors blockade on the delay-based decision-
making
3.3.1. Differential delay
After recovery and retraining, on the test day, the animals were
administrated withSB334867 (3, 30 and 300 μM/0.5 μl DMSO) or
DMSO 20%and were tested for differential delay task. Two-way re-
peated measure ANOVA followed by Bonferroni test [Treatment effect:
F(2,22)= 10.57, P < .0002; Day effect: F(3,66)= 43.39, P < .0001;
Treatment × Day: F(9,66)= 5.85, P < .0001)] revealed that blockade
of OFC OX1 receptors significantly attenuated HRC percentage and in
these animals, HRC percent significantly decreased compared to ve-
hicle-control group (Fig. 5A).In addition, there is no significant differ-
ence between the high dose of antagonist (300 nM) with the vehicle
group (Fig. 5A).
3.3.2. Equal delay
In this experiment introducing 15 s delay for both HR and LR caused
animals to shift to HRA after OX1r blocked by SB334867(30 μM/0.5 μl
DMSO). Two-way repeated measure ANOVA followed by Bonferroni
test [Treatment effect: F(1,9)= 3.74, P= .0852; Day effect: F
(3,27)= 1.64, P= .2034; Treatment × Day: F(3,27)= 0.29, P= .83)]
revealed that in equal control task, SB334867-treated animals preferred
high/delay reward and there was not a significant reduction in HRC
percentage compared to vehicle-control group (Fig. 5B).
3.4. Effect of OFC OX1 receptors on transient and decision-making time in
delay-based decision-making
The results showed [Treatment effect: F(3,18)= 0.48, P= .70; Day
effect: F(3,54)= 4.28, P= .0088; Treatment × Day: F(9,45)= 0.83,
P= .5)] showed that administration of different doses of SB334867 into
the OFC had no effect on transient time (latency of passing entrance
arm)compared to vehicle-control group (Fig. 6A), and also in equal
control task, administration of SB334867 (30 μM) [Treatment × Day: F
(3,27)= 0.61, P= .61); Day effect: F(3,27)= 1.08, P= .3731, Treat-
ment: F(1,9)= 4.86, P= .055] (Fig. 6B).
Two-way repeated measure ANOVA followed by Bonferroni test
showed that administration of different doses of SB334867 led to in-
crease of decision time in the rat [Day effect: F(3,63)= 6.99,
P < .0004; Treatment × Day: F(9,63)= 3.20, P= .003)] but there is
no difference between treatments [Treatment effect: F(3, 21)= 1.38,
P= .275].The results showed that intra- OFC administration of
SB334867 (30 μM) had a significant effect on decision time(P < .01)
group(Fig. 7A). On the other hand, in equal control task, administration
of SB334867 (30 μM) led to increase of decision time for reward
achievement [Treatment effect: F(1,10)= 11.05, P= .0077; Day effect:
F(3,30)= 3.96, P= .0173; Treatment × Day: F(3,30)= 2.99,
P= .0046)] compared to DMSO-control group (Fig. 7B).
Fig. 3. (A) Intra- ACC injection of SB334867 (3, 30 and 300 μM/0.5 μl DMSO) on test day decreased percent of high reward choice. (B) The performance on a control
task in which the same group of rats had passed the barrier to receive reward in both goal arms. Data show as mean ± SEM for 6–8 rats.
** P < .01; ***P < .001; ****P < .0001 different from the vehicle-control group.
Fig. 4. (A) Administration of SB334867 (3, 30 and 300 μM/0.5 μl DMSO) into the ACC on the test day had no effect on transient time for reward achievement. (B)
Administration of SB334867 (3, 30 and 300 μM/0.5 μl DMSO) into the ACC on the test day had no effect on decision time of choosing an arm. Data show as
mean ± SEM for 5–6 rats.
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3.5. Effect of ACC/OFC OX1 receptors on locomotor activity
The distance traveled following SB334867 treatments in the ACC/
OFC areas was calculated during 10min, and it suggested that loco-
motor activity has not changed by OX1 receptors antagonist, as shown
in Supplementary Fig. 1. This was confirmed by paired t-test, t
(6)= 0.9437, P= .3817 (OFC) and, t(5)= 0.9151, P= .4021 (ACC).
4. Discussion
This study aimed to define the possible effect of OX1r on the two
most important regions of the prefrontal cortex (ACC and OFC) on cost-
benefit decision-making. The main finding of the present study was that
the OX1r inactivation in the OFC substantially decreases rat's pre-
ference for high reward in delay-based decision- making task. In addi-
tion, the blockade of OX1r could increase the decision-making time
during the task but it had no effect on transient time. Also, the present
effort-based task results revealed that the OX1 receptor antagonist in
the ACC reduced the effort required to receive a high reward, but it had
no effect on the decision-making time during the task and also on the
transient time. On the other hand, locomotor activity was tested and the
results showed that OX1r inactivation had no effect on it.
The shift from a high reward to a low reward may be result of 1) a
change in value encoding, 2) a difference in cost encoding or 3) a
change in processing cost-benefit computations. To distinguish between
these possibilities, we designed a task with an equal cost for both arms
(HRA or LRA). The SB334867 administration in the mPFC areas in the
equal task was due to select HRA by animals, this result supports the
hypothesis that in the differential task the results do not purely depend
on reward value choice. Also, the equal tasks have indicated that the
presentation of the cost may not be a certain cause for selecting the LR
arm in the cost differed tasks. A proper hypothesis is that OX1 receptors
in these areas are required not only for value or cost encoding but also
for cost-benefit computations. These experiments emphasized that or-
exin 1 mediates pathways which are important for allowing animals to
overcome costs such as delay or effort –related cost to obtain high re-
wards.
These effects were specific to a reduction in motivation to achieve a
high reward, and not due to the effect of SB334867 on locomotors
activities. SB334867 had no effect during equal cost test, showing that
it did not affect the animals' power to move towards the high rewards.
Therefore, the current data demonstrated that SB334867 specifically
reduced HRA selection in both forms of decision-making task, in
agreement with the proposed role of orexin in controlling behavior
under a motivational state. It appears that blocking OX1r in this region
decreases motivation for performing an action (Mahler et al., 2014;
Saper, 2006; Sakurai, 2014).
This is the first demonstration that orexin signaling via OX1r in the
mPFC (ACC and/or OFC) may play a critical role in mediating cost and
benefit decision-making tasks. However, these findings match other
recent studies implicating orexin as important for decision-making
(Borgland et al., 2009; Karimi et al., 2017; Thompson and Borgland,
2011) and motivational behavior.
This result of a reduction in motivation for a high reward by
SB334867 could be achieved by either direct or indirect effect via
glutamatergic neurons or GABAergic neurons. Notably, cell bodies of
Fig. 5. (A) Microinjection of SB334867 (3, 30 and 300 μM/0.5 μl DMSO) into the orbitofrontal cortex on test day decreased percent of high reward choice. (B) The
performance on a control task in which the same group of rats had to wait (15 s) to receive reward in both goal arms. Data show as mean ± SEM for 5–7 rats.
** P < .01; **** P < .0001 different from the vehicle-control group.
Fig. 6. (A) Administration of SB334867 (3, 30 and 300 μM/0.5 μl DMSO) into the OFC on the test day had no effect on transient time. (B) The performance on a
control task in which the same group of rats had to wait (15 s) to receive reward in both goal arms. Data show as mean ± SEM for 5–6 rats.
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the glutamatergic neuron project to the NAc shell, including the pre-
frontal cortex and basolateral amygdala, which express OX1r (Trivedi
et al., 1998; Marcus et al., 2001). Furthermore, the OX1r promotion of
glutamate release has been demonstrated in other brain regions such as
the VTA (Borgland et al., 2009; Borgland et al., 2006; Wang et al.,
2009) amygdala (John et al., 2003), nucleus accumbens (Patyal et al.,
2012) and hippocampus (Stanley and Fadel, 2011). In previous studies,
Aracri et al. demonstrate that in the PFC, the application of orexin
excited fast-spike interneurons, causing the release of GABA onto pyr-
amidal cells and this effect was mediated by OX1rs (Aracri et al., 2013;
Burdakov et al., 2003).
Therefore, it is feasible that activation of OX1r on glutamatergic
neurons may affect the release output to other brain regions. Further
studies are required to investigate this possibility.
On the other hand, the reduction of interest for having the high
reward may be due to the effect of orexin on glutamatergic, dopami-
nergic and also GABAergic neurons indirectly via the cannabinoid re-
ceptor 1 (CB1) or OX1r heteromultimers. OX1 receptors seem to form a
homomeric and heteromeric complex (Xu et al., 2011). The previous
research confirmed the capacity of the CB1 and OX 1 receptors to in-
teract directly and showed that this complex could regulate with orexin
A. orexin A has a higher potency to CB1-OX1 heteromer compared with
OX1-OX1 homomer. CB1 antagonist could affect the function of orexin
A and this disruption could suggest interplay between these two sys-
tems that may modulate appetite, feeding, and wakefulness (Xu et al.,
2011; Ward et al., 2011). Our results may be affected by crosstalk be-
tween these neurotransmitter via the OX1-CB1 heteromer.
Endocannabinoid and orexinergic systems are also involved in the
regulation of the mesocorticolimbic reward system, a circuit re-
sponsible for the pleasurable feelings associated with natural rewards
and the consumption of drugs of abuse (Flores et al., 2013). Glutamate
synaptic transmission in the NAc and VTA, mainly from neurons of the
PFC, is similarly modulated by the activation of CB1 receptors (Melis
et al., 2004). The final effect of endocannabinoids on the modulation of
dopaminergic activity, which depends on the functional balance be-
tween these GABAergic and glutamatergic inputs, is predominantly
excitatory (Maldonado et al., 2006). The enhancement in dopamine
extracellular levels in the NAc induced by Δ(9)-tetrahydrocannabinol
was blocked in mice lacking the OX1 (Flores et al., 2014). Tung and his
colleges found that orexin A inhibited GABAergic transmission onto
dopaminergic neurons in VTA slices via a presynaptic mechanism. This
effect was antagonized by OX1r and CB1r antagonists (Tung et al.,
2016). They have described that during stress, orexin release in the VTA
and activate postsynaptic OX1 receptors on dopaminergic neurons.
Activation of the OX1 receptor leads to generate an endocannabinoid,
then this endocannabinoid travels across the synapse to inhibit GABA
release by activating presynaptic CB1 receptors on the GABAergic
terminal (Tung et al., 2016).These data show the interaction between
orexin and cannabinoid and may some similar mechanism occurs
during decision-making in the mPFC and OX1 receptors antagonist
could inhibit the release of dopamine in the same region in other region
by the mPFC projection.
On the other hand, our pervious result showed that the cannabinoid
agonist changes the preference of rat to choose the HRA and the agonist
disrupt decision-making (Khani et al., 2015). Perhaps the effect of
cannabinoid receptor agonist and orexin 1 receptor antagonist on the
decision-making correlates with the crosstalk between these neuro-
transmitters and the contribution between these two neurotransmitters
for regulating others like glutamate, dopamine and GABA in other brain
region. The previous study has been shown that cannabinoids reduced
the activity of orexin neurons in the lateral hypothalamus by pre-
synaptic attenuation of glutamate release (Huang et al., 2007). Perhaps
the same mechanism occurs in the mPFC and it should be investigated
more.
Interestingly, here it was found that the microinjection of SB334867
in the OFC affect decision- making in a dose dependent manner. It was
found that the microinjection of SB334867 (30 nM/0.5 μl) had a highly
significant disruption in decision-making and the high dose of the OX1r
antagonist (300 nM/0.5 μl) had no effect on delay-based decision-
making. Some evidence showed the dose dependent effect of SB334867
in other research like, anxiety (Staples and Cornish, 2014), food intake
(Rodgers et al., 2001) and also in the release of dopamine in the NAc
before administration of risperidone (Rasmussen et al., 2007). It has
been suggested that Orexin could be both anxiogenic and anxiolytic in
the investigation of rodent models (Kukkonen and Leonard, 2014).
The roles of OFC and ACC's OX1rs on the decision-making time and
transient time were studied. There was no observed significant differ-
ence in transient time in both tasks, which suggests that orexin 1 in
these regions, did not act while passing the entrance arms. Conversely,
even though SB334867 treatment in the OFC increased decision-
making time, it had no effect on decision-making time when it was
administrated in the ACC. Furthermore, the examination of the loco-
motor activity has demonstrated that OX1 has not been able to affect
locomotor activity. So this increase of decision-making time is not result
of the locomotor activity disruption. This strongly suggests that
SB334867 in the OFC increased decision-making time and it appears
that OX1r could accelerate process which leads to decision. Perhaps
orexin has a role in time of calculation of the cost and benefit in the
delay-based decision- making but not in effort-based decision- making.
Early experiments indicated that the OFC plays a crucial role in deci-
sion-making and planning, judging whether the decisions made had
failed and had long term severe consequences and also, in the ability to
identify and recall the implied meaning or importance of events/si-
tuations (Steiner, 2014). The previous study has provided evidence that
Fig. 7. (A) Administration of SB334867 (3, 30 and 300 μM/0.5 μl DMSO) into the OFCon test day increased decision time for reward achievement.(B) The per-
formance on a control task in which the same group of rats had to wait (15 s) to receive reward in both goal arms. Data show as mean ± SEM for 6 rats.
** P < .01; *** P < .001 different from the vehicle-control group.
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OFC is causally required for confidence reporting independent of per-
ceptual decision-making (Lak et al., 2014). Previously, Kepecs found
that rat OFC contains an explicit representation of decision confidence
(Kepecs et al., 2008). Also, OFC has been implicated in goal-directed or
intentional decisions requiring the evaluation of predicted outcomes
(Wallis, 2007; Padoa-Schioppa and Assad, 2006; Rolls and Grabenhorst,
2008; Schoenbaum et al., 2009; Kennerley et al., 2011).
The main part of the neurobiology of decision-making focuses on
“what is it?” Before making a decision neurons accumulate information
about the stimulus in the form of slowly increasing firing rates and
reach a decision when those firing rates reach a threshold (Sadacca
et al., 2016). The blockade of the OX1 receptor may affect the accu-
mulation of the stimuli in the OFC and it has increased decision-making
time. So, the preference of lesser reward observed although the time
increase in the different cost task.
In summary, this study showed that pharmacological OX1r blockade
in the anterior cingulate cortex and orbitofrontal cortex, especially
decreased high reward choices in the cost and benefit decision-making
tasks. This disruption in decision- making by OX1r antagonism also
increased decision-making time in the delay-based task. This finding
clearly revealed that orexin signaling via OX1r at the OFC and ACC is
critical for having decisions that optimize the reward magnitude in cost
and benefit decision-making tasks. Also, the OFC region played a cru-
cial role in a decision time.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.pnpbp.2018.09.006.
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